|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||261.316 g/mol|
3',4'-Methylenedioxy-α-pyrrolidinobutyrophenone (MDPBP) is a stimulant compound developed in the 1960s, which has been reported as a novel designer drug, often sold under the name "NRG-1" as a mixture with other substituted cathinone derivatives, including flephedrone, pentylone, MαPPP and MDPV.
The main metabolic steps are thought to be demethylenation followed by methylation of one hydroxy group, aromatic and side chain hydroxylation, oxidation of the pyrrolidine ring to the corresponding lactam as well as ring opening to the corresponding carboxylic acid. CYP2C19 and CYP2D6 have been identified as the isoenzymes mainly responsible for demethylenation.
As of October 2015 MDPBP is a controlled substance in China.
- α-Pyrrolidinobutiophenone (α-PBP)
- 3,4-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP)
- Methylenedioxypyrovalerone (MDPV)
- US3478050, Koeppe, Ludwig and Zeile, "1-(3',4'-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1)"
- Westphal F, Junge T, Klein B, Fritschi G, Girreser U. Spectroscopic characterization of 3,4-methylenedioxypyrrolidinobutyrophenone: a new designer drug with α-pyrrolidinophenone structure. Forensic Science International. 2011 Jun 15;209(1-3):126-32. PMID 21316166